Overall Survival in Phase III SUNRISE Subgroup Receiving Subsequent Immune Checkpoint Inhibitors

os_km_sact_with_io_28febos

Modified from Kallinteris NL et. al., AACR 2017

Format

PNG

Quelle:

Peregrine Pharmaceuticals Inc.

Downloads